BioSpace News Archive

ONO PHARMA USA , INC announced the initiation of a Phase 1 study of ONO-4685, an anti-PD-1/CD3 bispecific antibody, in patients with relapsed or refractory T-cell Lymphoma in the U.S.

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021, after the close of the stock market.

Aurion Biotech today announced the company’s medical advisory board, composed of the world’s most eminent ophthalmologists.

IASO Biotherapeutics has appointed Dr. Alan Fu as Chief Financial Officer (CFO), reporting to Maxwell Wang, CEO, IASO Bio.

Libra Therapeutics, Inc. today announced the appointment of Philip Lambert, Ph.D., as the company’s first chief scientific officer.

Ocugen, Inc. today announced that its head of Research and Development, Arun Upadhyay, PhD, will present pre-clinical data demonstrating how the company’s second modifier gene therapy candidate, OCU410 , could potentially be an effective therapeutic for Dry Age-related Macular Degeneration (Dry AMD).

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company will donate 100,000 vials of Veklury® (remdesivir) to help address the recent surge of COVID-19 cases in Indonesia and 3,000 vials of Veklury to help patients hospitalized with COVID-19 in Armenia.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered into an agreement with Beam Therapeutics Inc. (NASDAQ: BEAM) for non-exclusive commercial rights to Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), today announces the publication of a study in the peer-reviewed, open-source journal, Diagnostics, validating the Company’s point of care FastPack® IP (“FastPack”) diagnostic test as comparable to an industry-leading laboratory method in determining thyroid stimulating hormone (TSH) levels in blood.

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the product launch in Japan for Hiyasta® tablets to treat relapsed and/or refractory (R/R) adult T-cell leukemia/lymphoma (ATLL).